ProFactor Pharma LTD
  • Home
  • About Us
  • Haemophilia
  • Technology
  • Team
  • Contact
  • News
Select Page

PFP executives visit Bio Farma to kick start Tech Transfer process – January 2023

by Richard Cruse | Jan 26, 2023 | News

ProFactor Pharma’s executive directors, Jaymin Amin, CEO, and Richard Cruse, CFO, visited PT Bio Farma (Persero) (BFI) who recently licensed PFP’s patented process to make low-cost Factor VIII treatment for Haemophilia A. Jaymin met with BFI’s CEO, Mr. Honesti Basyir,...
Low-cost Haemophilia A treatment deal unlocks world of opportunity 

Low-cost Haemophilia A treatment deal unlocks world of opportunity 

by Richard Cruse | Oct 19, 2022 | News

The patented process to make low-cost treatment for Haemophilia A, developed by Scottish biotechnology company ProFactor Pharma Ltd (PFP), has taken an important step closer to market.  The successful completion of a Product Development, Technology Transfer and...

ProFactor Pharma (PFP) realise further capital injection – August 2022

by Richard Cruse | Sep 20, 2022 | News

ProFactor Pharma is pleased to announce completion of a further investment round. The investment will enable PFP to progress the company’s clinical stage Recombinant Human Factor VIII to market and to engage with commercial licensing opportunities. The funding...

Health Tech World – Interview – Ending the Haemophilia Drug Shortage (23 November 2021)

by Richard Cruse | Nov 24, 2021 | News

Published on November 23, 2021 By Deborah Johnson Interview: Ending the haemophilia drug shortage Jaymin Amin, CEO of ProFactor Pharma (PFP), discusses the company’s life-changing, and lifesaving, work. PFP says it has developed a low-cost production process for...

Profactor Pharma Announces Issuance of Indian and Eurasian Patent Covering a high yielding cell line for treatment of Haemophilia A

by Richard Cruse | Mar 31, 2021 | News

ProFactor Pharma Ltd (PFP) the developer of a unique, ultra high yielding cell line for the manufacture of recombinant human factor VIII (rhVIII), is pleased to announce the recent issuance of Indian Patent No. 361851 and Eurasian Patent No 529615EA. This patent...
« Older Entries

Articles

  • PFP executives visit Bio Farma to kick start Tech Transfer process – January 2023 January 26, 2023
  • Low-cost Haemophilia A treatment deal unlocks world of opportunity  October 19, 2022
  • ProFactor Pharma (PFP) realise further capital injection – August 2022 September 20, 2022
  • Health Tech World – Interview – Ending the Haemophilia Drug Shortage (23 November 2021) November 24, 2021
  • Profactor Pharma Announces Issuance of Indian and Eurasian Patent Covering a high yielding cell line for treatment of Haemophilia A March 31, 2021
  • Profactor Pharma completes optimisation of process for manufacture of lowest cost recombinant FVIII January 31, 2021
  • World-wide inequalities in Haemophilia care. Things are getting better? January 19, 2021
  • Outstanding technical progress July 15, 2020
  • Too many Haemophilia A patients still receiving inadequate or no treatment January 26, 2020
  • Paul Gerskowitch Joins PFP Board November 15, 2019
  • Home
  • About Us
  • Haemophilia
  • Technology
  • Team
  • Contact
  • News